Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

StanChart in $1.5bn buyback as annual earnings rise

(Sharecast News) - Asia-focused bank Standard Chartered said it would hand back $1.5bn to shareholders after a rise in annual earnings driven by its pursuit of wealthy customers, although it warned that global growth could be hit by protectionist trade policies amid threats of widespread tariffs by the new US government. Pre-tax profits for 2024 came in at $6bn, up from $5.1bn a year earlier and slightly below average estimates of $6.2bn. Unlike other banks reporting this week, StanChart also managed to lift its net interest margin - the difference between savings and lending rates - by 27 basis points to 1.94%.

Operating income rose 14% to $19.7bn boosted by a record performance in the wealth division, which grew 29%, and strong double-digit growth in global markets and global banking.

The bank said it attracted 265,000 new affluent clients, bringing in $44bn of net new money, up 61% year-on-year.

StanChart expects global growth to be broadly flat in 2025, moderating slightly to 3.1% from 3.2% last year, but then accelerating in 2026 to 3.3%. Its Asia, Africa and Middle East markets were expected to outpace the rest of the world.

"Support from looser financial conditions and expansionary fiscal policy may be partly offset by protectionist trade policies and interest rates that remain high," the bank said, adding that its own 2025 income growth was expected to be below the 5 - 7% range excluding notable items.

"We produced a strong set of results in 2024. Our strategy of combining differentiated cross-border capabilities for corporate and institutional clients with leading wealth management expertise for affluent clients is firing on all cylinders, driving an increase in return on tangible equity to 11.7%," said chief executive Bill Winters.

StanChart is investing $1.5bn over five years in wealth and digital platforms, client centres, people and brand and marketing, to accelerate income growth and returns.

"We are confident that our increased investment and greater concentration will help us to outperform the market in terms of asset gathering and income growth over the medium term," Winters said.

Interactive Investor head of markets Richard Hunter said: "Despite the headwinds of its exposure to China and the real estate sector in particular, where its presence has been something of a double-edged sword, the group's general exposure to Asia has offset any immediate concerns."

"After some years in the doldrums having once been the darling of the UK banking sector, Standard finds itself in something of a revival. Prior to this update, the shares had risen by 90% over the last year, as compared to a rise of 13% for the wider FTSE 100. This was driven only in part by a previously rebuffed takeover from First Abu Dhabi Bank, but rather more on prospects particularly throughout emerging markets."

"With such a stellar price run, the shares do not look obviously cheap and Standard will need to deliver on its projections for the next leg of growth. Even so, the strength of this update could well prompt an upgrade to a market consensus which currently stands at a hold, albeit a strong one."

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.